Healthcare services and CRO concept stocks continued to weaken, and Aoyang Health hit a standstill, and Novo Zhiyuan, Baihua Pharmaceuticals, Wanbang Pharmaceuticals, Gloria Ying, and Nanmo Biotech followed suit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.